Clinical Trials
116
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (115 trials with phase data)• Click on a phase to view related trials
Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma
- First Posted Date
- 2013-08-05
- Last Posted Date
- 2020-09-21
- Lead Sponsor
- NCIC Clinical Trials Group
- Registration Number
- NCT01916187
- Locations
- 🇨🇦
CHU Sainte-Justine, Montreal, Quebec, Canada
BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma
- Conditions
- Colorectal Carcinoma
- Interventions
- First Posted Date
- 2013-04-12
- Last Posted Date
- 2023-08-28
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 282
- Registration Number
- NCT01830621
- Locations
- 🇦🇺
Bankstown/ Lidcombe, Bankstown, New South Wales, Australia
🇦🇺Townsville Hospital, Douglas, Queensland, Australia
🇦🇺Flinders Medical Centre, Bedford Park, South Australia, Australia
A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma
- First Posted Date
- 2012-07-27
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 12
- Registration Number
- NCT01652144
- Locations
- 🇨🇦
CancerCare Manitoba, Winnipeg, Manitoba, Canada
🇨🇦QEII Health Sciences Centre, Halifax, Nova Scotia, Canada
🇨🇦Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia
- First Posted Date
- 2012-06-25
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 7
- Registration Number
- NCT01627054
- Locations
- 🇨🇦
CancerCare Manitoba, Winnipeg, Manitoba, Canada
🇨🇦Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma
- First Posted Date
- 2011-12-06
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 17
- Registration Number
- NCT01486368
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦BCCA - Fraser Valley Cancer Centre, Surrey, British Columbia, Canada
🇨🇦BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
- Prev
- 1
- 2
- 3
- 4
- 5
- 24
- Next